Silence Therapeutics Plc Stock Alpha and Beta Analysis
| SLN Stock | USD 6.60 0.15 2.33% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Silence Therapeutics PLC. It also helps investors analyze the systematic and unsystematic risks associated with investing in Silence Therapeutics over a specified time horizon. Remember, high Silence Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Silence Therapeutics' market risk premium analysis include:
Beta 1.86 | Alpha (1.53) | Risk 6.29 | Sharpe Ratio (0.22) | Expected Return (1.37) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Silence |
Silence Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Silence Therapeutics market risk premium is the additional return an investor will receive from holding Silence Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Silence Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Silence Therapeutics' performance over market.| α | -1.53 | β | 1.86 |
Silence Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Silence Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Silence Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Silence Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Silence Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Silence Therapeutics shares will generate the highest return on investment. By understating and applying Silence Therapeutics stock market price indicators, traders can identify Silence Therapeutics position entry and exit signals to maximize returns.
Silence Therapeutics Return and Market Media
The median price of Silence Therapeutics for the period between Sat, Sep 14, 2024 and Fri, Dec 13, 2024 is 17.99 with a coefficient of variation of 31.19. The daily time series for the period is distributed with a sample standard deviation of 4.73, arithmetic mean of 15.15, and mean deviation of 4.16. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Silence Therapeutics Sees Large Volume Increase - MarketBeat | 09/25/2024 |
2 | Some Shareholders Feeling Restless Over Silence Therapeutics plcs PS Ratio | 10/04/2024 |
3 | Silence Therapeutics Insider Ups Holding During Year | 11/13/2024 |
4 | Silence Therapeutics Zerlasiran Has Competitive Concerns Analyst | 11/19/2024 |
5 | SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels | 11/20/2024 |
6 | Redmile Group LLC Sells 114,979 Shares of Silence Therapeutics plc - MarketBeat | 12/05/2024 |
7 | Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology Annual Meeting | 12/09/2024 |
8 | Silence Therapeutics Given Buy Rating at Chardan Capital | 12/12/2024 |
About Silence Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Silence or other stocks. Alpha measures the amount that position in Silence Therapeutics PLC has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 249.52 | 361.68 | 270.9 | 257.35 | PTB Ratio | 61.38 | 18.39 | 29.71 | 31.2 |
Silence Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Silence Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Silence Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Silence Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Silence Therapeutics. Please utilize our Beneish M Score to check the likelihood of Silence Therapeutics' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Silence Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Silence Therapeutics Backtesting, Silence Therapeutics Valuation, Silence Therapeutics Correlation, Silence Therapeutics Hype Analysis, Silence Therapeutics Volatility, Silence Therapeutics History and analyze Silence Therapeutics Performance. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Silence Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.